SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaChronic neutrophilic leukemia: a clinical perspectiveRecurrent SETBP1 mutations in atypical chronic myeloid leukemiaThe Basic Biology of PP2A in Hematologic Cells and MalignanciesGAS6 expression identifies high-risk adult AML patients: potential implications for therapyFrom the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesPhosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridizationAlteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemiaSubclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemiaTherapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid LeukemiaLow expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsSETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.The recurrent chromosomal translocation t(12;18)(q14~15;q12~21) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondrolipoma.Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia developmentRUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.Somatic SETBP1 mutations in myeloid malignanciesThe new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatmentGenetic and epigenetic variants contributing to clofarabine cytotoxicity.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.Protein phosphatase 2A: a target for anticancer therapy.PP2A-Mediated Anticancer Therapy.-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.The Interplay between PP2A and microRNAs in Leukemia.Genomics of chronic neutrophilic leukemia.Somatic SETBP1 mutations in myeloid neoplasms.Acute myeloid leukemia: leukemia stem cells write a prognostic signature.A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia.
P2860
Q26752430-FE920FB1-8D52-47E2-A509-A56519121735Q26781167-896E9237-0A4F-4100-88CE-D6C9D9FD607AQ27851991-87E811FE-779D-451A-9F9B-F2256A8E7C4EQ28088697-8123ACB4-97BE-437D-9DE5-AA19AE3EBDC3Q33717707-63CB6720-320F-4E8B-9BA7-3D79DE1407CEQ34043449-537AA360-961A-429A-8A84-21432C25E101Q34051988-03506A03-4B5D-480E-9C1A-1D5BBBD32210Q34260622-73C0A2CA-1FD1-4576-9CC4-05AA5062FCE3Q34268171-5E8D3126-76B2-4B53-810E-B89AB51458E1Q34749589-B65B2C0A-B6B7-426B-BC8A-47D66766B268Q34974064-516E4E4A-DB40-49A5-BF80-A7DF91766760Q35037262-069EDBD7-5178-4C6B-88E1-C7BF6B4BEEA0Q35316765-8C34D75F-408D-4DCE-B027-FFDFD6DE7CB4Q35552005-07F698A4-1831-40F7-B71E-7ADCD7C1852DQ35849733-737B1C30-0F44-4EA4-A1C0-F47A9469D5B3Q35939513-606A65C9-DF44-42CB-96EC-CC3C0A97CA9CQ35944719-8D7D910F-83A2-48E7-9E19-FD5B84436CC6Q36057892-B3831E60-C65C-4376-8809-98D0B137F078Q36270003-AD8A3150-A5A0-4799-B8D2-458499DD283BQ36323864-049E6897-9F98-4C34-9BE0-72494EAB3CF4Q36437137-78B338FC-0B21-4825-B44C-8C967933FCF1Q36662047-F2616B67-8AAD-42C3-B910-30E1F9BA73FFQ37060418-5F195C76-CE4B-41D8-8635-71DDB6E20EAEQ37151676-6F265CD4-F8E6-40F8-89A5-CE187EFEC7C8Q37153800-2BC8AD7C-CFD2-4CC3-B7C6-1B14FDEDC7A7Q37641562-5735172B-72B6-4A3B-A8D6-53EB504D47C1Q37699236-A48E3B16-07EC-4018-BA16-721AEF1ABD5CQ37707099-78832C10-A00B-4D0C-81B9-ED26A8A392F2Q37708933-A79D07E8-27E9-4509-83A8-B2208D50F843Q37741358-3B392C8A-D102-464E-A329-33AD262169B3Q38062865-019D8522-4E9F-421B-AD3B-B0655AC56A0CQ38103646-7DEB3EA1-AEF1-4944-8FD6-2C1FE49B2589Q38168831-00951562-C723-4018-9D7F-0E34C2849E8EQ38226741-B3B61ABA-F18C-477A-B404-88DC772D162BQ38248429-2CB5EB87-CC59-4942-951F-C740EE61D302Q38370368-622D7038-00D4-4A6D-A800-E3E362152000Q39059515-2BE53E7B-AF6B-48D3-8B2A-08F3EA795432Q39266051-E7935A84-0B9C-4CC5-829A-9E8BFF36F6BFQ39448082-CF02E344-4860-4814-AE93-1F56E61B525CQ40725420-74C64B53-6080-44B0-B8F2-AE5C3B204C2B
P2860
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@en
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@nl
type
label
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@en
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@nl
prefLabel
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@en
SETBP1 overexpression is a nov ...... s with acute myeloid leukemia.
@nl
P2093
P50
P921
P1433
P1476
SETBP1 overexpression is a nov ...... ts with acute myeloid leukemia
@en
P2093
Carmen Vicente
Eva Bandres
Ion Cristóbal
José Rifon
Laura Garcia-Orti
María D Odero
María J Calasanz
Nerea Marcotegui
P304
P356
10.1182/BLOOD-2009-06-227363
P407
P577
2009-11-16T00:00:00Z